What Happens During an IVIG Infusion for CIDP? A Session From Check-In to Going Home

The chair is bigger than you expected. It reclines, there is a blanket folded on the armrest, and a nurse is already asking how you take your coffee. Somewhere behind you a pump is beeping in a steady rhythm. You came in worried about a needle; what you had not pictured was the waiting, the small talk, and a bag of clear fluid that will take most of a morning to empty.

That is the ordinary reality of an ivig infusion for cidp, and what to expect is mostly quiet time punctuated by careful checks. Chronic inflammatory demyelinating polyneuropathy is a condition in which the immune system attacks the insulating coating around peripheral nerves, causing weakness, numbness, and tingling that build over weeks or months. Intravenous immunoglobulin, or IVIG, is one of the first treatments neurologists reach for.

This explainer walks through a single session from the front desk to the drive home, and then through the days that follow, using what the evidence actually shows rather than what people fear or hope.

How does IVIG work in CIDP, in plain language?

Immunoglobulin is another word for antibody, the Y-shaped protein your immune system uses to tag invaders. IVIG is a purified concentrate of these antibodies pooled from the plasma of thousands of healthy blood donors, screened and processed so it can be given into a vein. It carries a broad mix of antibodies rather than one targeted drug.

Nobody can point to a single switch that IVIG flips in CIDP. The National Institute of Neurological Disorders and Stroke describes the treatment as one that suppresses the misdirected immune activity driving the disease. Laboratory work suggests several overlapping mechanisms: the infused antibodies may neutralize the harmful autoantibodies attacking myelin, dampen the complement system (a cascade of proteins that punches holes in cell membranes), and quiet the immune cells that keep the inflammation going. In everyday terms, IVIG floods the system with so many ordinary antibodies that the rogue ones lose their grip.

Myelin is the fatty insulation wrapped around nerve fibers, much like the plastic coating on an electrical cord. When it is stripped away, signals slow down or fail, which is why people with CIDP describe legs that feel like they belong to someone else. IVIG does not rebuild that insulation directly. It reduces the attack so the body’s own repair processes have room to work, which is why the benefit is measured over weeks rather than hours.

Because the effect fades as the infused antibodies are cleared, IVIG is usually repeated at intervals your neurologist sets and adjusts. The 2021 European Academy of Neurology and Peripheral Nerve Society guideline rates IVIG as a first-line option for typical CIDP, alongside corticosteroids, based on randomized trials.

IVIG infusion for CIDP: what to expect at check-in

Most infusions happen in an outpatient infusion suite, a hospital day unit, or, in some regions, at home with a visiting nurse. The setting changes the scenery but not the sequence.

Arrival starts with paperwork you have likely seen before: identity confirmation, allergy review, and a consent form if this is your first course. A nurse will then take baseline vital signs, meaning blood pressure, pulse, temperature, and breathing rate. These numbers matter more than they look. Every later reading during the infusion is compared against them, so a small drift in pulse or temperature can be caught early.

Expect a short set of questions. Have you had a fever or infection in the past few days? Any new medicines? How did the last infusion go? Did you drink enough water this morning? Hydration comes up repeatedly because immunoglobulin is a concentrated protein solution, and being well hydrated is one of the simplest ways to reduce headache and kidney strain, both of which are recognized IVIG-related concerns in the Cleveland Clinic and NINDS patient material.

If your team has ordered premedication, this is when it is given. Some centers offer an over-the-counter pain reliever or an antihistamine beforehand to blunt common reactions; others do not, and the decision rests with your prescribing clinician. Do not take anything extra on your own before arriving.

Then you settle in. The recliner, the blanket, the tray table, and a call button are standard. If you brought a companion, most units allow one visitor. The first bag is typically not hung until the nurse has double-checked the product label against your orders, a two-person verification that is routine for blood-derived therapies.

Getting the IV started and the pre-infusion checks

The needle moment is shorter than the dread. A nurse places a small plastic catheter, usually in the back of the hand or forearm, secures it with clear tape, and flushes it with saline to confirm it runs freely. People with fragile or hard-to-find veins sometimes have a port, a small device implanted under the skin of the chest that gives repeated access without hunting for a vein. Whether a port makes sense is a conversation for your neurology and infusion teams, not something decided in the chair.

Before the immunoglobulin itself is connected, several checks happen in quick succession. The nurse confirms the product lot number and records it, because IVIG is made from donated plasma and traceability is part of the safety framework. The line is primed. The pump is programmed with the starting rate ordered by your clinician. Emergency medicines for allergic reactions are within reach, as they are for any infusion unit.

You may notice a bag of plain saline running alongside or before the IVIG. This is deliberate. Pre-hydration through the vein is a common precaution in people with any kidney concern, and many units use it routinely to ease the load of a concentrated protein infusion.

Ask what rate the pump will start at and how often the nurse plans to check you. Knowing the plan reduces the small anxieties that pile up during a long sit. The start is always slow, a fraction of the eventual rate, because most infusion reactions cluster in the first hour and are strongly related to how fast the antibody solution enters the bloodstream.

What actually happens hour by hour during the drip

The first thirty minutes are the watchful stretch. The pump runs at its lowest setting, and the nurse checks vital signs at short intervals, often every fifteen minutes. This is not because trouble is expected; it is because a rate-related reaction announces itself early, and slowing the pump usually settles it.

If those first checks are steady, the rate is stepped up in stages. Each increase is followed by another set of vital signs. By the second hour most people are at the maximum rate their clinician has ordered, and the checks space out to every half hour or hour. A full session commonly runs between two and five hours, sometimes longer if the volume is large or the rate has to be kept low, a range consistent with the individualized dosing approach described in the EAN/PNS guideline. Your team will tell you the expected length for your specific order.

The middle hours are quiet. People read, work on a laptop, nap, or talk to whoever is in the next chair. You can stand and walk to the restroom with the pump on its wheeled pole. You can eat and drink, and staff will usually encourage water throughout.

Two physical sensations are worth knowing about so they do not alarm you. A cool feeling along the arm near the IV site is normal as room-temperature fluid enters the vein. Mild flushing, a headache that creeps in, or a chill is common and should be mentioned promptly rather than endured, because the nurse can slow the pump.

The bag empties, the line is flushed with saline to deliver the last few milliliters, and the pump goes silent. That is not quite the end of the session.

What should you watch out for during an IVIG infusion?

Most reactions during IVIG are mild and tied to infusion rate. Knowing which sensations to report quickly turns you from a passive passenger into part of the safety system.

Say something right away if you notice a headache starting or building, chills or shivering, a warm flush across the face or chest, nausea, back or flank ache, muscle aches, or a general sense of feeling unwell. None of these is dangerous in itself, but each is a cue for the nurse to slow or pause the pump, recheck your vitals, and possibly give a comfort measure your clinician has already approved. In most cases the infusion resumes at a gentler pace once symptoms fade.

A smaller group of symptoms means stop and call for help immediately, not at the next scheduled check: difficulty breathing or a tight chest, wheezing, swelling of the lips, tongue, or throat, hives spreading over the skin, dizziness with a sense of fainting, or a racing heartbeat. These can signal a true allergic reaction. They are uncommon, and infusion units are set up precisely for them, but speed matters.

Pay attention to the IV site too. Burning, swelling, or a hard cord along the vein can mean fluid is leaking into the tissue or the vein is irritated, and the line may need to be repositioned.

Two practical habits help. Keep drinking water unless you have been told to limit fluids. And do not stay silent to be polite. Infusion nurses would far rather slow a pump ten times than miss the one occasion that mattered. The MedlinePlus overview of CIDP treatment and the NINDS page both list these reactions as recognized, manageable parts of IVIG therapy.

IVIG side effects for CIDP: common, uncommon, and rare

Side effects sort neatly by timing and likelihood, and seeing them laid out tends to shrink the fear rather than feed it. The categories below reflect how mainstream sources such as the Cleveland Clinic, NINDS, and the EAN/PNS guideline describe IVIG tolerability. Frequencies are given as clinical impressions, not percentages, because reported rates vary widely by product, rate, and patient.

Category	Examples	Typical timing	What usually helps
Common, mild	Headache, chills, low-grade fever, fatigue, nausea, flushing, muscle or back ache	During infusion or within 1-2 days	Slower rate, hydration, rest; clinician-approved comfort medicines
Uncommon	Rash or hives, blood pressure changes, aseptic meningitis (a severe headache with neck stiffness and light sensitivity that is inflammatory, not infectious)	Hours to 3 days after	Medical assessment; usually settles with supportive care and rate adjustment next time
Rare, serious	Blood clots, kidney injury, hemolysis (breakdown of red blood cells), severe allergic reaction	During or within days	Urgent evaluation; risk factors are screened for before each course

Two patterns are worth understanding. First, most reactions are dose-and-rate phenomena rather than allergies, which is why the same person can have a rough first session and smooth later ones once the rate is tuned. Second, the rare serious events cluster in people with identifiable risk factors: existing kidney disease, dehydration, a history of clots, heart failure, or very thick blood. That is why the pre-infusion questions feel repetitive. They are the screening.

Your team may check kidney function and blood counts periodically. If anything in the rare category is suspected, the infusion is stopped and you are assessed, and a different product or approach may be chosen for future courses.

IVIG headache after infusion: why it happens and what usually helps

Ask anyone who has had several courses of IVIG what they remember most and the answer is often the headache. It is the single most talked-about side effect, and understanding it makes it easier to manage.

The likely mechanism is a mix of factors. A large volume of concentrated protein changes the osmotic balance of the blood, drawing fluid across membranes. The infusion can mildly irritate the meninges, the membranes covering the brain and spinal cord. And dehydration, which is common when people skip breakfast and sit for hours, magnifies both effects. The result ranges from a dull pressure that fades by evening to a pounding headache that lasts a day or two.

Aseptic meningitis is the severe end of this spectrum. The word aseptic means no infection is present; the inflammation is a reaction to the product. It tends to appear within a few days, brings neck stiffness, light sensitivity, and sometimes vomiting along with the headache, and is uncomfortable but usually resolves with supportive care. It is uncommon, and people who have had it once are often given a slower rate or a different product next time.

What helps is unglamorous. Drinking water steadily the day before, during, and the day after. Asking for a slower infusion rate if you have had headaches before. Taking only the comfort medicines your clinician has approved, at the timing they suggest. Resting in a dim room afterward rather than pushing through a full workday.

The headache is not a sign that the treatment is failing or that nerve damage is worsening. It is a side effect of the delivery, not the disease. Report it at your next visit so the rate and premedication plan can be adjusted; these are the two levers your team can actually pull.

Going home: the final half hour and the ride

When the last of the saline flush has run through, the nurse does not immediately pull the catheter. Most units keep you seated for an observation period, commonly around twenty to thirty minutes, so that any delayed reaction surfaces while help is nearby. A final set of vital signs is taken and compared with your baseline from check-in.

The IV is removed, pressure is applied for a minute or two, and a small dressing goes on. Expect the site to be slightly tender and perhaps faintly bruised for a couple of days; a hard, hot, or increasingly swollen site is different and should be reported.

Before you leave, you should receive or already have three things: the date of your next infusion or a plan for scheduling it, a phone number to call for problems that arise at home, and clear instructions on which symptoms are routine and which are urgent. If premedication made you drowsy, or if you feel light-headed, you will be asked to wait longer or to have someone drive.

Many people feel tired the evening after an infusion, a flat, heavy fatigue rather than sleepiness. Plan for it. The first course, especially, is not the day to schedule anything demanding afterward. A light meal, plenty of water, and an early night are the usual advice.

Treat the ride home as part of the session. If you have a long drive, stop and walk for a few minutes every hour or so; the infusion, the sitting, and the concentrated protein together nudge clotting risk upward in people who already carry risk factors, and gentle movement is the simplest counterweight.

How long does IVIG take to work for CIDP, and what do the next weeks look like?

The honest answer is that nothing dramatic happens on infusion day. IVIG is not a drug that switches symptoms off; it removes a brake on recovery, and recovery is slow.

In the randomized trials summarized by the EAN/PNS guideline, improvement in strength and function was typically measured over the first several weeks after starting treatment, and initial courses are often assessed at around the six-week mark before deciding whether to continue. Some people notice steadier footing or easier stair climbing within two to three weeks; others need a second or third course before anything shifts. The guideline notes that in the pivotal trial cited, roughly half of those on IVIG met the improvement threshold compared with about one in five on placebo, a reminder that response is common but not universal.

The days right after an infusion are often a small dip: fatigue, perhaps a headache, a feeling of being wrung out. That usually clears within a day or two. Then, for many, comes a plateau or gradual gain that lasts until the infused antibodies are cleared, at which point symptoms may creep back. This wear-off pattern is why maintenance infusions are spaced at intervals your neurologist adjusts based on how long your benefit lasts. Keeping a simple diary of grip strength, walking distance, and tingling helps your team see the curve.

What you feel is only half the picture. Neurologists track objective measures such as grip dynamometry, timed walks, and disability scales. Nerve conduction studies, tests that measure how fast electrical signals travel along a nerve, may be repeated less often. Improvement in these measures, not just a good day, is what guides the decision to continue, adjust, or switch.

Who is IVIG usually for, and who is usually asked to wait?

IVIG is a first-line treatment for CIDP, but first-line does not mean automatic. The decision to use it, and when, follows a fairly consistent logic in mainstream guidance.

It is usually offered to people with a confirmed diagnosis of typical CIDP whose weakness or sensory loss is progressing or clearly limiting daily function. The EAN/PNS guideline places IVIG alongside corticosteroids as a reasonable first choice, and IVIG is often preferred when steroids are risky, for example in people with poorly controlled diabetes, significant osteoporosis, or a history of psychiatric reactions to steroids. It is also frequently chosen for pure motor CIDP, a variant with weakness but little sensory loss, because steroids can sometimes worsen that form.

Some people are asked to wait or to consider alternatives first. Those with very mild, stable symptoms may be monitored rather than treated, since IVIG is a long-term commitment with real side effects. People with significant kidney disease, a recent blood clot, uncontrolled heart failure, or a known severe reaction to immunoglobulin products need careful risk assessment, product selection, or a different treatment altogether. An active infection is a reason to postpone a session rather than cancel treatment.

Diagnosis matters enormously here. Several conditions mimic CIDP, and some, such as neuropathy from diabetes or from certain antibody-related disorders, do not respond to IVIG. The Johns Hopkins patient material stresses that electrodiagnostic testing and, in selected cases, spinal fluid analysis or nerve imaging are used to confirm the diagnosis before committing to treatment.

None of these judgments belong in a magazine article. They sit with the neurologist who has your test results, your history, and your goals in front of them.

Does IVIG repair nerve damage?

Not directly, and the distinction shapes what recovery realistically looks like.

Peripheral nerves have two components that fail in CIDP. Myelin, the insulating sheath, is the primary target of the immune attack, and it can regrow relatively quickly once the attack is suppressed, sometimes over weeks. The axon, the long wire inside the sheath that actually carries the signal, is not the primary target but gets damaged as a bystander when demyelination is severe or prolonged. Axons regenerate slowly, on the order of about an inch a month at best, and sometimes not at all.

IVIG works on the first problem. By calming the immune assault, it allows the body’s own Schwann cells, the cells that manufacture myelin, to rewrap exposed nerve segments. That is why people whose disease is caught early, before much axon loss, often regain a great deal of function, while those treated after years of untreated progression may stabilize but not fully recover. The NINDS page frames the goal of CIDP treatment as reducing symptoms and preventing further damage, language that deliberately avoids promises of reversal.

Nerve conduction studies illustrate the point. After successful treatment, conduction velocity often improves as myelin returns, but the amplitude of the signal, which reflects how many axons survived, may not. Your neurologist reads both numbers.

This is the strongest evidence-based argument for not delaying evaluation when weakness is progressing. It is not fear-marketing; it is anatomy. The treatment protects what is still intact and gives the repairable parts time to repair. It cannot rebuild wire that is already gone, which is exactly why realistic expectations, set early with your team, make the long road easier to walk.

How does IVIG compare with other CIDP treatments?

IVIG shares the first-line shelf with two other approaches, and a third is increasingly used for maintenance. Understanding the trade-offs helps you follow your team’s reasoning without trying to make the decision yourself.

Corticosteroids, a class of anti-inflammatory hormones, are the oldest treatment for CIDP. They are taken orally or given as periodic intravenous pulses, and they work by broadly suppressing immune activity. The EAN/PNS guideline considers them an equally reasonable first choice for typical CIDP. Their appeal is convenience; their drawback is a long list of effects with prolonged use, including bone thinning, weight gain, raised blood sugar, and mood change. They are generally avoided in pure motor CIDP.

Plasma exchange, also called plasmapheresis, is a procedure in which blood is drawn, the liquid plasma containing antibodies is removed and replaced, and the blood is returned. It works quickly but requires large-vein access and repeated sessions, and its benefit fades fast. It is usually reserved for severe or rapidly worsening disease, or when IVIG and steroids have not helped.

Subcutaneous immunoglobulin delivers the same antibody concentrate under the skin, often at home, using a small pump over an hour or two, several times a month. It avoids vein access and the peak-and-trough swings of intravenous dosing. Many people who stabilize on IVIG are later offered it as a maintenance option.

For those who do not respond adequately to first-line treatment, immunosuppressant medicines are sometimes added, though the guideline notes the evidence for most of them is weaker. Every one of these choices involves weighing your disease pattern, other health conditions, vein access, lifestyle, and preferences, which is a conversation, not a formula.

What people often get wrong about IVIG for CIDP

Myths gather around any long-term treatment, and IVIG collects more than most because it is made from human blood and given for a condition few people have heard of.

The first misconception is that a bad first infusion means the treatment will not work or cannot be tolerated. Most early reactions are rate-related, not allergic, and adjusting the pump speed, hydration, or product usually solves them. Effectiveness and side effects are largely independent.

The second is that feeling nothing on infusion day means it is not working. IVIG suppresses an immune process; the nerves then need weeks to respond. The absence of an immediate effect tells you nothing about the eventual outcome.

The third is that IVIG carries a meaningful risk of transmitting infection. Modern immunoglobulin products go through donor screening, testing, and multiple viral inactivation and removal steps. Transmission of known blood-borne viruses through current IVIG products is not a documented ongoing risk in mainstream guidance, which is why it is not listed among the side effects patients are warned about.

The fourth is that once symptoms improve, treatment can simply stop. Some people do achieve remission and can pause under supervision, and the guideline recommends periodically testing whether treatment is still needed. But stopping on your own, without a plan, risks a relapse that may be slower to recover from. That decision belongs with your neurologist.

The fifth is that IVIG interferes with everything. It does affect the timing of live vaccines such as measles or varicella, because the infused antibodies can neutralize the vaccine virus, and the CDC advises spacing them apart. Most other medicines and inactivated vaccines are not affected. Tell your team about every vaccine and new prescription, and let them do the sorting.

CIDP infusion day tips and questions to ask your care team

A little preparation shaves the rough edges off a long session, and a few well-chosen questions make the whole course easier to navigate.

On the practical side, eat a normal breakfast and start drinking water the day before unless told otherwise. Wear layers with sleeves that push up easily past the elbow; infusion rooms run cold and chills are common. Bring something to do for four hours, a phone charger, and a snack. Write down any symptoms since your last session and any new medicines or supplements, including over-the-counter ones. If you have had headaches before, mention it at check-in rather than at the end.

Questions worth asking your neurologist or infusion team, ideally before the first course and again as treatment settles:

• What rate will the infusion start at, and how quickly will it be increased?
• Which comfort medicines, if any, are you recommending before or after, and when should I take them?
• How will you decide whether the treatment is working, and when will we first assess that?
• What signs should make me call the same day, and what can wait for the next visit?
• How will the interval between infusions be set, and what happens if symptoms return early?
• Are my kidney function and blood counts being monitored, and how often?
• Do I need to adjust the timing of any vaccines?
• Is home infusion or subcutaneous immunoglobulin something to consider later, and what would need to be true for that?
• What is the plan if I do not respond after the initial course?

Keep the answers somewhere you can find them. Treatment for CIDP unfolds over months and years, and the person who remembers the original plan is often you.

When to call your doctor

Most of what follows an IVIG infusion is mild and predictable. A few things are not, and knowing the difference is part of being safely treated at home between sessions.

Seek emergency care immediately, by calling your local emergency number, for any of the following: difficulty breathing, chest pain or pressure, swelling of the face, lips, or throat, sudden weakness or numbness on one side of the body, trouble speaking, sudden severe headache unlike any you have had, or a painful swollen calf or leg, especially if accompanied by shortness of breath. These can indicate a severe allergic reaction, a stroke, or a blood clot in the leg or lung, all of which are rare but recognized risks with immunoglobulin therapy.

Call your neurology or infusion team the same day, without waiting for your next appointment, if you develop a headache with neck stiffness, light sensitivity, or vomiting within a few days of the infusion, a fever that persists beyond a day, a widespread rash or hives, dark or reddish urine or a sharp drop in how much urine you pass, yellowing of the skin or eyes, unusual bruising, or an IV site that becomes hot, red, hard, or increasingly painful.

Contact your team within a few days, not urgently, if your CIDP symptoms seem to be returning earlier than they did after previous infusions, if fatigue or headache lasts longer than usual, or if you have started a new medicine or been offered a vaccine.

You are not overreacting by calling. Infusion teams expect these calls, and every report helps them tune the next session. The single most protective habit in long-term CIDP care is a low threshold for picking up the phone.

Frequently asked questions

How long does it take for IVIG to start working for CIDP?

Most people notice no change on infusion day and begin to see improvement over the following two to six weeks, with a formal assessment often made around the six-week mark. Some require a second or third course before strength or walking improves. Response varies, and your neurologist uses objective measures such as grip strength and timed walks, not just how you feel, to judge whether to continue.

How long does it take to feel better after an IVIG infusion?

The first day or two after an infusion often brings fatigue or a headache rather than improvement. Any benefit builds gradually over subsequent weeks as the immune attack quiets and myelin begins to recover. In people on maintenance infusions, benefit may plateau and then fade as the antibodies are cleared, which is why the interval between sessions is adjusted to how long your improvement lasts.

What should I watch out for during an IVIG infusion?

Report headache, chills, flushing, nausea, back ache, or feeling generally unwell as soon as they start, so the nurse can slow the pump. Call for help immediately if you have trouble breathing, chest tightness, wheezing, hives, swelling of the lips or throat, or a racing heartbeat, which can signal a true allergic reaction. Burning or swelling at the IV site also needs attention.

Does IVIG repair nerve damage from CIDP?

Not directly. IVIG suppresses the immune attack, giving the body’s own myelin-producing cells room to rewrap damaged nerves, which can happen over weeks. It does not regenerate axons, the inner wires of the nerve, which regrow slowly or not at all once lost. That is why people treated early, before significant axon damage, generally regain more function than those treated after years of progression.

What are the most common IVIG side effects for CIDP?

Headache, chills, low-grade fever, fatigue, nausea, flushing, and muscle or back aches are the most common, usually appearing during the infusion or within a day or two and settling on their own. Less often, people develop a rash or aseptic meningitis, a non-infectious inflammatory headache with neck stiffness. Rare but serious events include blood clots, kidney injury, red blood cell breakdown, and severe allergic reactions.

Why do I get a headache after an IVIG infusion?

The concentrated protein solution shifts fluid balance in the blood, can mildly irritate the membranes around the brain, and is often compounded by dehydration from a long session. Drinking water steadily before, during, and after the infusion, asking for a slower rate, and using only the comfort medicines your clinician approves are the main ways to reduce it. A severe headache with neck stiffness or light sensitivity should be reported the same day.

How often are IVIG infusions given for CIDP?

An initial course is typically given over several consecutive days, followed by maintenance infusions spaced weeks apart. The exact interval is individualized by your neurologist according to how long your improvement lasts before symptoms begin to return, and it is adjusted over time. Guidelines also recommend periodically reassessing whether treatment is still needed, since some people achieve remission.

Can I drive home after an IVIG infusion?

Many people do, but it depends on how you feel and whether you received premedication that causes drowsiness. Light-headedness, a heavy headache, or fatigue are reasons to have someone else drive, particularly after a first course when your response is unknown. On longer trips, stopping to walk briefly every hour helps offset the small increase in clotting risk associated with prolonged sitting after immunoglobulin.

Can IVIG for CIDP be given at home?

In many regions, yes. Home infusion with a visiting nurse follows the same sequence of vital-sign checks, slow start, and observation as a clinic session, and is usually offered once a person has tolerated several infusions in a supervised setting. Subcutaneous immunoglobulin, delivered under the skin with a small pump, is another home-based option some people move to for maintenance. Suitability is decided by your treating team.

What are the alternatives to IVIG for CIDP?

Corticosteroids are an equally recognized first-line option for typical CIDP, though they are generally avoided in the pure motor form. Plasma exchange, which removes antibody-containing plasma from the blood, is usually reserved for severe or rapidly worsening disease. Subcutaneous immunoglobulin is a maintenance alternative, and immunosuppressant medicines are sometimes added when first-line treatments have not helped. The choice depends on your disease pattern and other health conditions.

References

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): National Institute of Neurological Disorders and Stroke (NIH)
• Chronic inflammatory polyneuropathy: MedlinePlus Medical Encyclopedia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.